145214-05-7Relevant articles and documents
THERAPEUTIC COMPOUNDS
-
Paragraph 00442-00443, (2021/06/04)
The present disclosure relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, and compositions and uses thereof. The compounds are useful as inhibitors of the YAP:TEAD protein:protein interaction. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various YAP:TEAD-mediated disorders, including cancer.
COMPOUNDS
-
Page/Page column 103-104, (2020/01/11)
A compound of formula (I), or a pharmaceutical salt thereof.
NOVEL ISOPHTHALATES AS BETA-SECRETASE INHIBITORS
-
Page/Page column 43-44, (2010/11/23)
There is provided a series of substituted isophthalates of formula (I) or a stereoisomer thereof; or a pharmaceutically acceptable salt thereof, wherein W, R3, R5 and R6 as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.
